Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Shares of Ventyx Biosciences Rose Monday

TheMotleyFool

0 0

Why Shares of Ventyx Biosciences Rose Monday: https://g.foolcdn.com/editorial/images/738460/physician-monitoring-patients-onscreen-vitals.jpg

On Monday, shares of Ventyx Biosciences (NASDAQ: VTYX) closed 22.87% higher than they did last week. The clinical-stage biotech hit more than $40 a share for the first time since March 10.

Ventyx focuses on therapies to treat inflammatory diseases and autoimmune disorders. The company has four programs in its pipeline, including two in phase 2 trials:

Investors looking for clues about how the programs are going got excited Monday even though the company reported through its Securities and Exchange Commission filings that several insiders were unloading company stock.

Source Fool.com

Like: 0

VTYX

Share